

## PRESS RELEASE

**EOS imaging Announces First Sale of EOS System in Israel**

*Tel Aviv Sourasky Medical Center first to offer the unique benefits of the EOS technology to patients in Israel*

**Paris, April 5<sup>th</sup> 2017, 6 pm CEST - EOS imaging (Euronext, FR0011191766 – EOSI)**, the pioneer in 2D/3D orthopedic medical imaging, today announced the first sale of an EOS platform in Israel to [Tel Aviv Sourasky Medical Center](#). The EOS platform has now been sold in 33 countries. The EOS platform is expected to be installed in April at [The Dana-Dwek Hospital](#), one of the four main hospitals that make up the Tel Aviv Sourasky Medical Center.

Tel Aviv Sourasky Medical Center (TAMC) is the second largest and one of the most progressive full-service healthcare treatment and research institutions in Israel. As a premier multidisciplinary academic medical center, the Center serves the greater Tel Aviv metropolitan area population of 3.5 million people accounting for over 42% of the entire population of Israel. TAMC is a national referral center for many major primary and specialty care services.

Marie Meynadier, CEO of EOS imaging, said, *“We are pleased that Tel Aviv Sourasky Medical Center is the first site in Israel to acquire an EOS platform. Given its status as a national reference site for orthopedic care, a large number of Israeli patients will now have access to our technology. In addition, this sale further expands our global installed base and provides incremental validation for the EOS system and associated services.”*

For more information, please visit [www.eos-imaging.com](http://www.eos-imaging.com).

**EOS imaging has been chosen to be included in the new EnterNext© PEA-PME 150 index, composed of 150 French companies and listed on Euronext and Alternext markets in Paris.**

EOS imaging is listed on Compartment C of Euronext Paris  
ISIN: FR0011191766 – Ticker: EOSI

**About EOS imaging**

EOS imaging designs, develops, and markets EOS<sup>®</sup>, an innovative medical imaging system dedicated to osteo-articular pathologies and orthopaedics, as well as associated solutions. The Company is authorized to market in 51 countries, including the United States (FDA), Japan and the European Union (EC). The Group posted 2016 revenues of €30.8 million and employs 132 people at December 2016, including an R&D team of 43 engineers. The Group is based in Paris and has five subsidiaries in Besançon (France), Cambridge (Massachusetts), Montreal (Canada), Frankfurt (Germany) and Singapore.



## PRESS RELEASE

### **Contacts:**

#### **Anne Renevot**

CFO

Ph: +33 (0)1 55 25 61 24

[investors@eos-imaging.com](mailto:investors@eos-imaging.com)

#### **NewCap**

Financial communication and investor relations

Pierre Laurent / Valentine Brouchet

Ph: +33 (0)1 44 71 94 96

[eosimaging@newcap.eu](mailto:eosimaging@newcap.eu)

Media Relations

Annie-Florence Loyer

Ph: +33 (0)1 44 71 00 12 / 6 88 20 35 59

#### **The Ruth Group (US)**

Press relations / Joanna Zimmerman

Ph: 646-536-7006

[jzimmerman@theruthgroup.com](mailto:jzimmerman@theruthgroup.com)